how long have people been using semaglutide Has Studied? Research Timeline How long does it take

Lu, Jie, Giuseppe Esposito, Caterina Scuderi, Luca Steardo, Laurent C

Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range

KFFs 2025 Employer Health Benefits Survey found a notable increase in the share of the largest employers that cover GLP-1 medications for weight loss in the past year

Shen, L., Weber, C